Multiple Myeloma

1.5 Credits / Oncology, Hematology, Hematologic Cancer

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Hematology, Hematologic Cancer, Oncology

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credit / Hematologic Cancer, Oncology

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.0 Credit / Oncology, Hematology, Hematologic Cancer

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

More News

April 3rd 2023

Characteristics of Relapse Affect Treatment Choices in Multiple Myeloma

Natalie S. Callander, MD, director of the University of Wisconsin Carbone Cancer Center Myeloma Clinical Program, reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.

March 30th 2023

Ide-Cel Shows Benefit vs Standard Regimens in Heavily Pretreated R/R Multiple Myeloma

Idecabtagene vicleucel (ide-cel) led to significantly longer PFS and better therapy responses than standard regimens for patients with triple-class–exposed relapsed and refractory multiple myeloma.

March 23rd 2023

Study Characterizes Infections in Patients Treated With Bispecific Antibodies for Multiple Myeloma

A recent study found that infection is a significant burden in patients with multiple myeloma who receive bispecific antibodies, and viral infections are the most common culprits.

March 15th 2023

The Information Patients Receive During Multiple Myeloma Treatment May Differ From What They Want to Know

There may be discrepancies in the types of information patients want and the information they receive when multiple myeloma treatment decisions are made, a recent study found.

March 9th 2023

Dr Ajai Chari: Patients in High-risk Subgroups Benefited From Daratumumab Plus Triplet

Ajai Chari, MD, professor of medicine and director of clinical research in the Multiple Myeloma Program at Mount Sinai in New York, discusses a post-hoc analysis of data from the phase 2 GRIFFIN trial.

Image of clinician running a multiple myeloma test: angellodeco - stock.adobe.com

March 6th 2023

Screening Protocols During Early Phase of COVID-19 Improved Outcomes in MM

Researchers retrospectively analyzed data from patients who visited 2 myeloma centers between March and October 2020, before vaccines were widely available but during large-scale implementation of regular screening processes.

March 3rd 2023

Diagnosis of Second Primary Malignancies Associated With Prolonged Survival Among Patients With MM

Matthew Gavidia

Incidences of certain second primary malignancies were associated with increased overall survival among patients with multiple myeloma in a retrospective analysis of real-world data.

March 1st 2023

Ide-Cel Shows Superior Survival in Hard-to-Treat Patients With R/R MM

Idecabtagene vicleucel (ide-cel) reduced the risk of disease progression or death by 51% in patients with triple-class–exposed relapsed or refractory multiple myeloma (R/R MM).

February 23rd 2023

Population-Based Study Finds Increased Risk of Stroke, Heart Attack in Patients With MM

Individuals with multiple myeloma were 51% more likely to have a stroke and 36% more likely to have a heart attack compared with the general patient population in a large real-world assessment of arterial thrombotic events among patients with multiple myeloma in the United States.

February 15th 2023

Throughout this study's 12-year period, the average annual percent change showed an uptrend for all groups in hospitalization for spinal cord compression (SCC), and this was higher for non-Hispanic Black patients vs Hispanic patients and non-Hispanic White patients.

February 8th 2023

Preferred Treatment Sequencing for Patients with MM

In the final discussion, expert panelists navigate treatment sequencing in MM treatment strategies.

February 8th 2023

Partnering Academic and Community Settings to Optimize Care for Patients with MM

Dr Nadeem provides community and clinical strategies to treat patients with MM.

February 8th 2023

Daily Physical Activity Has Positive Impact on Immune Stimulation in MM

The effects of physical activity and exercise have previously been reported, with data pointing to improvements in quality of life as well as such clinical markers as immune response in tumors

February 5th 2023

Allogeneic Stem Cell Transplant Shows Minimal OS, PFS Benefits in MM

Although allogenic stem cell transplant is increasingly used to treat multiple myeloma (MM) and other hematological conditions, there have been mixed efficacy results in the context of MM.

February 3rd 2023

Including MRD Status Reduces Uncertainty in Long-term Survival Models of NDMM

Having models like these that produce more plausible results are crucial for decision-making in an era of targeted treatments that often come with immature data, argued researchers of their findings for minimal residual disease (MRD) in newly diagnosed multiple myeloma (NDMM).

February 1st 2023

Differences in Care Between Academic and Community Settings in Multiple Myeloma

Dr Lipe shares disparities between academic and community practice settings for patients with MM.

February 1st 2023

Updates in NCCN Guidelines of Frontline Treatment for MM

Highlighted are updates in NCCN guidelines for frontline MM treatment strategies.

January 29th 2023

Griffin: Daratumumab Plus RVd Improved Responses for Older and Some High-Risk Patients Compared With Triplet Alone in Newly Diagnosed MM

The analysis, which was presented during the 64th ASH Annual Meeting and Exposition, highlighted stringent complete response data for patients 65 years and older and those with high cytogenic risk.

January 25th 2023

In Community-Based Study, Switching to Ixazomib in Newly Diagnosed MM Brought Improved Responses Across Age Groups

An analysis presented during the 64th American Society of Hematology Annual Meeting and Exposition showed that patients with multiple myeloma were able to experience improved responses to the proteasome inhibitor ixazomib after switching from bortezomib.

January 25th 2023

Product Preference with NCCN Category 1 Status

Dr Haumschild leads a discussion regarding frontline MM treatment products as categorized by NCCN.

January 25th 2023

Providing Incentives for Provider Adherence to MM Pathway

Raymond Thertulien, MD, PhD, highlights provider incentives for adherence to MM treatment pathways.

January 20th 2023

Study Finds Ixazomib Beneficial in MM Patients With High-Risk Cytogenic Traits